Should I buy or sell OptiNose stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OPTN shares. View OPTN analyst ratings or view top-rated stocks .

What is OptiNose's stock price target for 2024?

3 analysts have issued 1-year price objectives for OptiNose's stock. Their OPTN share price targets range from $3.00 to $5.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 331.9% from the stock's current price. View analysts price targets for OPTN or view top-rated stocks among Wall Street analysts .

How have OPTN shares performed in 2024?

OptiNose's stock was trading at $1.29 at the start of the year. Since then, OPTN stock has decreased by 28.2% and is now trading at $0.9261. View the best growth stocks for 2024 here .

When is OptiNose's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our OPTN earnings forecast .

How were OptiNose's earnings last quarter?

OptiNose, Inc. (NASDAQ:OPTN) posted its quarterly earnings results on Thursday, March, 7th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01. The firm earned $19.87 million during the quarter, compared to analyst estimates of $19.90 million. During the same quarter last year, the business posted ($0.17) earnings per share.

What guidance has OptiNose issued on next quarter's earnings?

OptiNose issued an update on its first quarter 2024 earnings guidance on Thursday, March, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $13.0 million-$13.0 million, compared to the consensus revenue estimate of $18.2 million.

What other stocks do shareholders of OptiNose own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OptiNose investors own include Proteostasis Therapeutics (PTI) , Idera Pharmaceuticals (IDRA) , Viking Therapeutics (VKTX) , Allena Pharmaceuticals (ALNA) , Dynavax Technologies (DVAX) , Matinas BioPharma (MTNB) , Selecta Biosciences (SELB) , VBI Vaccines (VBIV) , Strongbridge Biopharma (SBBP) and SCYNEXIS (SCYX) .

When did OptiNose IPO?

OptiNose (OPTN) raised $101 million in an IPO on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO.

How do I buy shares of OptiNose?

Shares of OPTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:OPTN

OptiNose (OPTN) Stock Price, News & Analysis

→ The #1 Opportunity of the decade? (From Behind the Markets) (Ad)

Free OPTN Stock Alerts

$0.89

-0.03 (-3.61%)

(As of 04:38 PM ET)

Compare

Today's Range: $0.89
▼
$0.97
50-Day Range: $0.93
▼
$1.94
52-Week Range: $0.89
▼
$2.10

Volume: 652,839 shs
Average Volume: 536,478 shs
Market Capitalization: $100.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Get OptiNose alerts:

OptiNose MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 331.9% Upside
$4.00 Price Target
Short Interest: Healthy
2.76% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.10
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$138,078 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.26) to ($0.12) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.09 out of 5 stars

Medical Sector

227th out of 918 stocks

Pharmaceutical Preparations Industry

89th out of 417 stocks

3.5

Analyst's Opinion

Consensus Rating
OptiNose has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
OptiNose has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.76% of the outstanding shares of OptiNose have been sold short.
Short Interest Ratio / Days to Cover
OptiNose has a short interest ratio ("days to cover") of 5.7.
Change versus previous month
Short interest in OptiNose has recently decreased by 2.81%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
OptiNose does not currently pay a dividend.
Dividend Growth
OptiNose does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
OptiNose has received a 60.30% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Sumatriptan", "Nasal medication (R01)", and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for OptiNose is -2.10.

N/A

News and Social Media Coverage

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, OptiNose insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $138,078.00 in company stock.
Percentage Held by Insiders
Only 2.20% of the stock of OptiNose is held by insiders.
Percentage Held by Institutions
85.60% of the stock of OptiNose is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for OptiNose are expected to grow in the coming year, from ($0.26) to ($0.12) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of OptiNose is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of OptiNose is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

The #1 Opportunity of the decade?

It's no wonder the Department of Defense is heavily invested in this technology. And why The Pentagon is pouring $20 billion into it.

Click here to learn more >>>

About OptiNose Stock (NASDAQ:OPTN)

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

OPTN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OPTN Stock News Headlines

March 20, 2024 | insidertrades.com

Michael F. Marino III Sells 15,059 Shares of OptiNose, Inc. (NASDAQ:OPTN) Stock

April 7, 2024 | msn.com

Optinose to Present at Needham Virtual Healthcare Conference

April 19, 2024 | Behind the Markets (Ad)

The #1 Opportunity of the decade?

It's no wonder the Department of Defense is heavily invested in this technology. And why The Pentagon is pouring $20 billion into it.

April 6, 2024 | finance.yahoo.com

OptiNose (NASDAQ:OPTN) shareholders have endured a 87% loss from investing in the stock five years ago

April 4, 2024 | globenewswire.com

Optinose to Present at the Needham Virtual Healthcare Conference

March 16, 2024 | finanznachrichten.de

Optinose, Inc.: XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

March 16, 2024 | msn.com

OptiNose granted FDA nod to expand labeling for sinusitis therapy

March 15, 2024 | bizjournals.com

Bucks County's Optinose wins FDA approval for wider use of flagship product

April 19, 2024 | Behind the Markets (Ad)

The #1 Opportunity of the decade?

It's no wonder the Department of Defense is heavily invested in this technology. And why The Pentagon is pouring $20 billion into it.

March 15, 2024 | globenewswire.com

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

March 13, 2024 | bizjournals.com

Optinose primed for FDA ruling on Xhance that could 'reshape' its future

March 10, 2024 | finance.yahoo.com

US$3.00: That's What Analysts Think OptiNose, Inc. (NASDAQ:OPTN) Is Worth After Its Latest Results

March 10, 2024 | seekingalpha.com

OptiNose, Inc. (OPTN) Q4 2023 Earnings Call Transcript

March 8, 2024 | finance.yahoo.com

OptiNose, Inc. (NASDAQ:OPTN) Q4 2023 Earnings Call Transcript

March 8, 2024 | finance.yahoo.com

OptiNose Full Year 2023 Earnings: EPS Beats Expectations

March 7, 2024 | finance.yahoo.com

OptiNose Inc (OPTN) Reports Decline in 2023 Revenue Amidst Preparations for Potential XHANCE ...

March 7, 2024 | investorplace.com

OPTN Stock Earnings: OptiNose Meets EPS, Beats Revenue for Q4 2023

March 7, 2024 | finanznachrichten.de

Optinose, Inc.: Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

March 7, 2024 | finance.yahoo.com

Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

March 7, 2024 | msn.com

OptiNose reports mixed results; initiates Q1 and FY24 outlook

March 7, 2024 | washingtonpost.com

OptiNose: Q4 Earnings Snapshot

March 7, 2024 | globenewswire.com

Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

March 6, 2024 | benzinga.com

OptiNose's Earnings: A Preview

February 29, 2024 | globenewswire.com

Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results

February 29, 2024 | entrepreneur.com

3 Pharma Stocks to Consider for March Gains

January 18, 2024 | finance.yahoo.com

Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice

December 6, 2023 | msn.com

Why ENT-Focused OptiNose Shares Are Diving Today

See More Headlines

Receive OPTN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OptiNose and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:OPTN
CUSIP: N/A
CIK: 1494650
Web: www.optinose.com
Phone: (267) 364-3500
Fax: N/A
Employees: 132
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.00
High Stock Price Target: $5.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +331.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.32)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-35,480,000.00
Net Margins: -50.06%
Pretax Margin: -49.99%
Return on Equity: N/A
Return on Assets: -33.05%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.60
Quick Ratio: 0.55

Sales & Book Value

Annual Sales: $70.99 million
Price / Sales: 1.47
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.77) per share
Price / Book: -1.20

Miscellaneous

Outstanding Shares: 112,650,000
Free Float: 110,174,000
Market Cap: $104.33 million
Optionable: Not Optionable
Beta: -0.24

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Dr. Ramy A. Mahmoud M.D. (Age 59)
M.P.H., CEO & Director
Comp: $731.59k
Mr. Michael F. Marino Esq. (Age 48)
Chief Legal Officer & Corporate Secretary
Comp: $604.24k
Mr. Anthony J. Krick (Age 43)
Vice President & Chief Accounting Officer
Mr. Jonathan Neely
Vice President of Investor Relations & Business Operations
Ms. Karen E. Brophy (Age 61)
Chief Human Resources Officer & VP of Human Resources
Mr. Paul Spence (Age 56)
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OPTN Stock Analysis - Frequently Asked Questions

Should I buy or sell OptiNose stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OPTN shares.
View OPTN analyst ratings or view top-rated stocks.
What is OptiNose's stock price target for 2024?: 3 analysts have issued 1-year price objectives for OptiNose's stock. Their OPTN share price targets range from $3.00 to $5.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 331.9% from the stock's current price.
View analysts price targets for OPTN or view top-rated stocks among Wall Street analysts.
How have OPTN shares performed in 2024?: OptiNose's stock was trading at $1.29 at the start of the year. Since then, OPTN stock has decreased by 28.2% and is now trading at $0.9261.
View the best growth stocks for 2024 here.
When is OptiNose's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our OPTN earnings forecast.
How were OptiNose's earnings last quarter?: OptiNose, Inc. (NASDAQ:OPTN) posted its quarterly earnings results on Thursday, March, 7th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01. The firm earned $19.87 million during the quarter, compared to analyst estimates of $19.90 million. During the same quarter last year, the business posted ($0.17) earnings per share.

What guidance has OptiNose issued on next quarter's earnings?: OptiNose issued an update on its first quarter 2024 earnings guidance on Thursday, March, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $13.0 million-$13.0 million, compared to the consensus revenue estimate of $18.2 million.
What other stocks do shareholders of OptiNose own?: Based on aggregate information from My MarketBeat watchlists, some companies that other OptiNose investors own include Proteostasis Therapeutics (PTI), Idera Pharmaceuticals (IDRA), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Selecta Biosciences (SELB), VBI Vaccines (VBIV), Strongbridge Biopharma (SBBP) and SCYNEXIS (SCYX).
When did OptiNose IPO?: OptiNose (OPTN) raised $101 million in an IPO on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO.
How do I buy shares of OptiNose?: Shares of OPTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OPTN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

OptiNose (OPTN) Stock Price, News & Analysis

OptiNose MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

Company Ownership

Earnings and Valuation

About OptiNose Stock (NASDAQ:OPTN)

OPTN Stock Price History

OPTN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

OPTN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™